Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Launched by YONSEI UNIVERSITY · Dec 10, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is focused on studying how circulating tumor DNA (ctDNA) can help in the diagnosis and monitoring of urological cancers, such as prostate, renal cell, bladder, and ureter cancers, particularly in the Korean population. As these types of cancers are becoming more common due to an aging population and lifestyle changes, researchers want to understand if ctDNA—pieces of genetic material found in blood and urine—can provide valuable information about the presence of cancer, how it's progressing, and how well treatments are working. The goal is to create a large database that can improve personalized medicine for patients with these cancers.
To participate in the study, individuals must have been diagnosed with one of the specified urological cancers and have undergone surgery at Severance Hospital between December 2019 and November 2029. Participants will need to give their consent to use their health information for research. Those who choose to join the study can expect to provide samples of their blood and urine, which will be analyzed to better understand their cancer. This research is important as it aims to enhance the way doctors can detect and treat urological malignancies using advanced genetic testing.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Patients diagnosed as urological malignances (prostate cancer, renal cell cancer, bladder cancer, and ureter cancer)
- • 2. Patients who have undergone surgeries due to urological malignancies in Severance Hospital, Sinchon from 2019.12 and 2029.11
- • 3. Those who agree to give permission to use their human source information - 4. Those who agree with this study
- Exclusion Criteria:
- • 1. Those who do not agree with this study
- • 2. Vulnerable participants who are likely to be vulnerable to coercion or undue influence or lack decision-making
About Yonsei University
Yonsei University, a prestigious institution located in South Korea, is renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, Yonsei University leverages its extensive expertise and innovative approaches in various fields of medicine to conduct rigorous clinical trials aimed at improving patient outcomes and advancing healthcare solutions. The university's robust infrastructure, multidisciplinary collaboration, and adherence to ethical standards ensure the integrity and reliability of its research initiatives, making it a key player in the global clinical research landscape.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials